Structure of human aldose reductase holoenzyme in complex with statil: An approach to structure-based inhibitor design of the enzyme

被引:31
作者
El-Kabbani, O
Ramsland, P
Darmanin, C
Chung, RPT
Podjarny, A
机构
[1] Monash Univ, Dept Med Chem, Victorian Coll Pharm, Parkville, Vic 3052, Australia
[2] ULP, INSERM, CNRS, IGBMC,UPR Biol Struct, Illkirch Graffenstaden, France
关键词
aldose reductase inhibition; drug design; X-ray crystallography; molecular modeling; ternary complex;
D O I
10.1002/prot.10278
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aldose reductase, a monomeric NADPH-dependent oxidoreductase, catalyzes the reduction of a wide variety of aldehydes and ketones to their corresponding alcohols. The X-ray structure of human aldose reductase holoenzyme in complex with statil was determined at a resolution of 2.1 Angstrom. The carboxylate group of statil interacted with the conserved anion binding site located between the nicotinamide ring of the coenzyme and active site residues Tyr48, His110, and Trp111. Statil's hydrophobic phthalazinyl ring was bound in an adjacent pocket lined by residues Trp20, Phe122, and Trp219, with the bromo-fluorobenzyl group penetrating the "specificity" pocket. The interactions between the inhibitor's bromo-fluorobenzyl group and the enzyme include the stacking against the side-chain of Trp111 as well as hydrogen bonding to residues Leu300 and Thr113. Based on the model of the ternary complex, the program GRID was used in an attempt to design novel potential inhibitors of human aldose reductase with enhanced binding energies of the complex. Molecular modeling calculations suggested that the replacement of the fluorine atom of statil with a carboxylate functional group may enhance the binding energies of the complex by 33%. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:230 / 238
页数:9
相关论文
共 44 条
[1]   Cross-validated maximum likelihood enhances crystallographic simulated annealing refinement [J].
Adams, PD ;
Pannu, NS ;
Read, RJ ;
Brunger, AT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (10) :5018-5023
[2]   The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity [J].
Barski, OA ;
Gabbay, KH ;
Bohren, KM .
BIOCHEMISTRY, 1996, 35 (45) :14276-14280
[3]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[4]   The structure of human aldose reductase bound to the inhibitor IDD384 [J].
Calderone, V ;
Chevrier, B ;
Van Zandt, M ;
Lamour, V ;
Howard, E ;
Poterszman, A ;
Barth, P ;
Mitschler, A ;
Lu, JH ;
Dvornik, DM ;
Klebe, G ;
Kraemer, O ;
Moorman, AR ;
Moras, D ;
Podjarny, A .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2000, 56 :536-540
[5]  
CHUNG S, 1989, J BIOL CHEM, V264, P14775
[6]   Pharmacological approaches to the treatment of diabetic complications [J].
Costantino, L ;
Rastelli, G ;
Gamberini, MC ;
Barlocco, D .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (08) :1245-1262
[7]   Modelling studies of the active site of human sorbitol dehydrogenase: An approach to structure-based inhibitor design of the enzyme [J].
Darmanin, C ;
El-Kabbani, O .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (24) :3133-3136
[8]   Aldose reductase and the role of the polyol pathway in diabetic nephropathy [J].
Dunlop, M .
KIDNEY INTERNATIONAL, 2000, 58 :S3-S12
[9]  
El-Kabbani O, 2000, PROTEINS, V41, P407, DOI 10.1002/1097-0134(20001115)41:3<407::AID-PROT120>3.0.CO
[10]  
2-9